Beam Therapeutics INC. 8-K Filing

Key Financial Figures

• $0.01 — ch registered Common Stock, par value $0.01 per share BEAM Nasdaq Global Select
• $255.1 million — hares were cancelled and converted into $255.1 million in closing cash consideration, plus the
• $26.3 million — he right to receive up to approximately $26.3 million in additional cash consideration upon t

Filing Documents

• beam-20251208.htm (8-K) — 42KB
• 0001193125-25-316043.txt ( ) — 142KB
• beam-20251208.xsd (EX-101.SCH) — 23KB
• beam-20251208_htm.xml (XML) — 4KB

01 Completion of Acquisition or Disposition of Assets

Item 2.01 Completion of Acquisition or Disposition of Assets. On December 8, 2025, Bristol-Myers Squibb Company ("BMS") completed its previously announced acquisition of Orbital Therapeutics, Inc. ("Orbital") pursuant to an Agreement and Plan of Merger dated October 10, 2025 between Orbital and BMS (the "Acquisition"). Prior to the closing of the Acquisition, Beam Therapeutics Inc. (the "Company") held 75 million shares of Orbital common stock, which represented a fully diluted ownership stake of approximately 17%. At the closing of the Acquisition, such shares were cancelled and converted into $255.1 million in closing cash consideration, plus the right to receive up to approximately $26.3 million in additional cash consideration upon the release, if any, of certain escrows. The Company plans to provide an update on its anticipated cash runway, taking into consideration proceeds from the Acquisition, in connection with the 2026 J.P. Morgan Healthcare Conference. Cautionary Note Regarding Forward-Looking Statements

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Beam Therapeutics Inc. Date: December 11, 2025 By: /s/ John Evans John Evans Chief Executive Officer